- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00658866
Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection (2007-005020-33)
Background/rationale: Ertapenem is an innovative antimicrobial agent, which is approved in the European Union for diabetic foot infections of the skin and soft tissue. Although its antimicrobial spectrum and activity against ESBL-strains are promising to treat infected ulcers associated with diabetes, there is a lack of data on tissue pharmacokinetics of ertapenem in this patient population. However, for antimicrobial efficacy it is important to show that the antibiotic achieves sufficient concentrations at the site of infection, i.e. in tissue. A recent clinical study by Burkhardt et al. (Journal of Antimicrobial Chemotherapy, 2006) using the microdialysis technique showed that the free tissue concentrations after a single dose of 1 g ertapenem are sufficient and adequate to kill most relevant bacteria, suggesting efficacy of ertapenem for soft tissue infections. It is well known that there is no accumulation of ertapenem in plasma after multiple doses of 1 g every 24 h in patients without significantly impaired renal function. The single dose study by Burkhardt et al. also suggests that only negligible drug accumulation can be expected in soft tissues of healthy young volunteers after multiple doses. However, it was shown for other antibiotics that tissue PK may be significantly different under pathologic conditions, leading to impaired penetration, but subsequent accumulation after multiple doses due to a longer tissue half life than in healthy volunteers. Since the properties of inflamed tissue may diverge from those of healthy tissue it is important to evaluate which concentrations of ertapenem are reached in inflamed tissue after multiple doses.
Clinical study: In the present study we will measure the concentrations of ertapenem over time in plasma and infected tissue of 10 diabetes patients after multiple doses. The microdialysis technique will be used. The ertapenem concentrations will be measured in inflamed tissue and in non-inflamed subcutaneous tissue to identify the effect of inflammation on pharmacokinetics. The findings of the present study will help to confirm the efficacy of ertapenem for the indication of diabetic soft tissue infections.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University Vienna, Department of Clinical Pharacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, aged between 18 and 85 years
- Diagnosis of Diabetes mellitus
- Clinically diagnosed skin or soft tissue infection and/or infected ulcers of the leg, requiring antimicrobial therapy
- Prescription of ertapenem for therapeutic reasons
- Willingness and ability to comply with the protocol
- Signed informed consent
Exclusion Criteria:
- HIV, Hepatitis B or C positive
- Allergy or hypersensitivity against study drug
- Severe renal impairment, defined by a serum creatinine level > 1.6 mg/L
- Pregnancy, or women of child bearing potential not willing to apply adequate contraception during study period
- Any disease considered relevant for proper performance of the study, or risks to the patient, at the discretion of the investigator
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics in tissue
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Erta_MD_1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Infection
-
University Hospital, GhentWithdrawnNecrotizing Soft Tissue InfectionBelgium
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Aarhus University HospitalRecruitingNecrotizing Soft Tissue InfectionDenmark
-
University of California, IrvineRecruitingNecrotizing Soft Tissue InfectionUnited States
-
Texas Tech University Health Sciences CenterCompletedNecrotizing Soft Tissue InfectionsUnited States
-
May AlrahiBaylor College of Medicine; Montefiore Medical Center; Maimonides Medical Center and other collaboratorsCompletedSoft Tissue InfectionUnited States
-
New York Medical CollegeTerminatedNecrotizing Soft Tissue InfectionUnited States
-
Kirby InstituteNot yet recruitingInvasive Fungal Infections | Infection, Bacterial | Infection, Fungal | Injection Site Infection | Infection, Soft Tissue | Invasive Bacterial Infection
-
Ascension Via Christi Hospitals Wichita, Inc.The University of Kansas School of Medicine - WichitaTerminatedSepsis | Necrotizing Soft Tissue InfectionUnited States
-
GlaxoSmithKlineCompletedSkin Diseases, Infectious | Infection, Soft TissuePakistan
Clinical Trials on Microdialysis
-
Barts & The London NHS TrustImperial College London; Queen Mary University of LondonRecruitingAortic Aneurysm | Aortic Diseases | Aortic Dissection | Aortic ArchUnited Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGlioblastoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Metastatic Malignant Neoplasm in the Brain | Diffuse GliomaUnited States
-
Centre Hospitalier Universitaire de Saint EtienneUniversity Hospital of Saint-EtienneTerminatedKidney Cancer | Nephrectomy | MicrodialysisFrance
-
Medical University of GrazCompleted
-
Accunea Ltd.Imperial College Healthcare NHS Trust; Hammersmith Hospitals NHS Trust; Innovate...Withdrawn
-
Imperial College LondonThe Drummond Foundation (RAMC charity)RecruitingCompartment Syndrome of Leg | Limb IschemiaUnited Kingdom
-
Mayo ClinicEnrolling by invitation
-
Medical University of GrazMenarini GroupCompleted
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Centre Hospitalier Universitaire, AmiensCompleted